Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This study is being done in order to determine the effectiveness of the combination of
fludarabine, mitoxantrone, and rituximab in patients with mantle cell lymphoma. All three
drugs,fludarabine, mitoxantrone, and rituximab have been approved by the U.S. Food and Drug
Administration (FDA)for the treatment of certain types of lymphoma. Rituximab is a drug
(called a monoclonal antibody) which has anti-tumor activity on certain types of lymphoma.
The combination of chemotherapy (fludarabine and mitoxantrone) with rituximab has not yet
been investigated in patients with mantle cell lymphoma and therefore the combination in
investigational.